Table 2 Characteristics of studies included based on treatment regimens: platin derivates (cisplatin or carboplatin) and anthracycline with/without taxanes
|  | Affiliation | Type of study | Stage of disease | Nº of BRCA1/2 mutated TNBC patients | pCR | Neoadjuvant treatment |
|---|---|---|---|---|---|---|
Saether 2018 [28] | Letonia | Retrospective | I-III | 10 | 8 | Cis—Dox |
Holanek 2019 [29] | Czech Republic | Retrospective | I-III | 37 | 21 | Cis- A (18) Cb-P-A (19) |
Zhang 2021 [34] | China | Retrospective | I-III | 18 | 9 | Cb-A-T |
Pohl-Rescigno 2020 GeparOcto [20] | Germany | RCT Phase III | I-III | 35 | 26 | Cb-Dox-P |
Loib Ann 2018 [22] | 15 countries North America Europe Asia–Pacific | RCT Phase III | II-III | 33 | 23 | Cb-Dox-P |